EOFLOW

EOFlow Officially Launches iOS Version of the EOPatch App ‘Narsha’

▶ iOS version of the world’s first app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable controller with a smartphone app EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announces that it officially launches iOS Version of ‘Narsha,’ a smartphone application for wearable insulin pump in Korea. It has been nine months since the Company officially launched the Android application of Narsha. Narsha is the world’s first...

May. 17. 2022
EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue

▶ Highest-ever quarterly revenue! Strong revenue growth from European sales; Menarini will progressively launch the product in Europe from 2Q22 onwards! ▶ EOFlow expects significant growth in revenue in 2022 from market launches in Europe, Indonesia, and the Middle East EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced its Q1 financial results ended on March 31, 2022. EOFlow announced its consolidated financial results: first quarter of 2022 revenue of 949 million Korean...

May. 16. 2022
EOFlow Has its First Clinical Study on EOPatch Published in Diabetes & Metabolism Journal

▶ A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus ▶ 4-week treatment with EOPatch was safe and led to clinically meaningful improvement in glycemic control compared to those with MDI or conventional insulin pump EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its first clinical study results on the wearable insulin pump EOPatch in patients with type 1 diabetes were publ...

Apr. 11. 2022
EOFlow to Supply KRW48.8bn Worth of EOPatch to Gulf Drug of UAE

▶ A Major Export Deal for EOFlow’s Innovative Insulin Pump EOPatch EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced on March 31 that it has signed a contract with GulfDrug LLC (Gulf Drug) of the United Arab Emirates (UAE) to supply 48.8 billion Korean won (40 million US dollar) worth of EOPatch, a disposable and wearable insulin pump, over the course of five years. The Company said the contract amount is equivalent to 7043 percent (%) of its entire sales last year. T...

Apr. 04. 2022
[Fierce Pharma] SanPlena sets out to show wearable patches are the key to faster weight loss

EOFlow's newly established joint venture 'SanPlena' was featured on this article on Fierce Pharma. This article is about EOFlow, Inc.’s newly established joint venture named SanPlena, which aims to develop innovative wearable drug delivery solutions for treatment of Obesity & NASH. Please find out more on the link below. Jan. 03, 2022 [Fierce Pharma] SanPlena sets out to show wearable patches are the key to faster weight loss https://www.fiercepharma.com/drug-delivery/sanplena-sets-out-to-show-wearable-patches-are-k...

Jan. 04. 2022
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH

▶ Establishment of Joint Venture Company named SanPlena in the US ▶ Drug-device combination of EOFlow’s smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. Sir Stephen Bloom, world-renowned researcher in the field of obesity and metabolism at Imperial College London (UK) ▶ 10-15% weight loss in 2-3 months eyed with the combination product EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its wholly owned US s...

Dec. 28. 2021
Menarini has won three tenders for 'GlucoMen Day PUMP' in Italy

Menarini has informed EOFlow that they have won three tenders for 'GlucoMen Day PUMP' in Italy. These are the first winning tenders for EOFlow's wearable insulin pump. Full details on tenders will be announced soon. [Attachment] Menarini's ‘GlucoMen Day PUMP'

Dec. 16. 2021
EOFlow Receives Approval of Investigational Device Exemption (IDE) Application for its Two-Part Wearable Artificial Pancreas “EOPatch X” for Pivotal Study on People with Type 1 Diabetes in Korea

▶ The pivotal clinical study will be conducted at nine leading university hospitals and involve over one hundred people with type 1 diabetes. It aims to obtain statistically significant evidence of efficacy and safety of “EOPatch X” ▶ “EOPatch X” is a two-part wearable artificial pancreas (AP) solution that automatically adjusts basal insulin delivery based on the user’s glucose level EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced that the C...

Dec. 14. 2021
EOFlow to Supply KRW45.3bn Worth of 'EOPatch' to Indonesian Company

A Major Export Deal for Innovative Insulin Pump EOFlow Co. Ltd., a provider of wearable drug delivery solutions, announced on Dec. 8 that it has signed a contract with PT. Prasasti Nusantara Sukses (PT. PNS) of Indonesia to supply 45.3 billion won worth of 'EOPatch,' a disposable and wearable insulin pump. The Company said the contract amount represented 209,316.90 percent of its sales last year. The contract period is until Dec. 5, 2026. Through this contract, PT. PNS will be granted exclusive sales rights in Indonesia for the innova...

Dec. 09. 2021
EOFlow Initiates Eco-Friendly Disposal Campaign for EOPatch in Korea Embracing and Integrating Environmental, Social, and Governance (ESG)

▶EOFlow will collect, process, and dispose of used EOPatch pumps in an environmentally safe manner ▶EOFlow will set up an Incentive Program for this Campaign EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced today that the Company is initiating an environmentally friendly disposal campaign to minimize the impact of used EOPatch pumps on the environment. As there are no environmental regulations or guidelines for proper disposal of used medical devices in Korea, used patc...

Nov. 09. 2021
EOFlow to Raise 100 Billion Korean Won and Offer Stock Split Capital Raised Will Be Used For Global Market Expansion

▶ 100 billion Won to be raised with new common stock offering, to be followed by a 2:1 stock split EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will raise some 100 billion Won with new common stock offering, after which it will do a 2:1 stock split. The Company will make a new public offering of its common stocks. The company will issue up to 3,000,000 shares of common stocks, representing 25.99% of the current total number of issued shares. The...

Oct. 28. 2021
EOFlow and Sinocare Establish a Joint Venture Company

▶ Sinocare is China’s Largest Diabetes Management Instrument Manufacturer ▶ Joint venture company to launch a full-scale effort for clinical study to obtain regulatory approval for EOPatch manufacturing and distribution in China ▶ High growth expected from EOPatch business in China where world’s largest diabetes population live EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will establish a joint venture company “SINOFLOW Co., Ltd...

Oct. 27. 2021
EOFlow Begins Clinical Study of its Wearable Insulin Pump “EOPatch” on People With Type 2 diabetes in Korea

▶ This clinical study involves ten leading university hospitals and up to one hundred and thirty-six people with Type 2 diabetes. It is Korea’s largest ever clinical study employing insulin pumps. ▶ This pioneering study aims to demonstrate and validate efficacy of EOPatch for Type 2 diabetes therapy. EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company completed enrollment of first patient in a clinical study on type 2 diabetes for its wearable in...

Oct. 14. 2021
EOFlow Completes its First Shipment to Europe

▶ EOFlow’s European exclusive distributing partner Menarini to showcase the EOPatch at EASD 2021 EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has made its first shipment to Europe today. After launching the wearable insulin pump in Korea this March and obtaining the CE certification in May, EOFlow is now expanding its reach to Europe, starting with the first shipment completed on September 30. EOFlow officially launched its EOPatch, Korea’s first (and the w...

Sep. 30. 2021

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here